Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,258 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Feasibility of methotrexate discontinuation following tocilizumab and methotrexate combination therapy in patients with long-standing and advanced rheumatoid arthritis: a 3-year observational cohort study.
Miyata M, Hirabayashi Y, Munakata Y, Urata Y, Saito K, Okuno H, Yoshida M, Kodera T, Watanabe R, Miyamoto S, Ishii T, Nakazawa S, Takemori H, Ando T, Kanno T, Komagamine M, Kato I, Takahashi Y, Komatsuda A, Endo K, Murai C, Takakubo Y, Miura T, Sato Y, Ichikawa K, Konta T, Chiba N, Muryoi T, Kobayashi H, Fujii H, Sekiguchi Y, Hatakeyama A, Ogura K, Sakuraba H, Asano T, Kanazawa H, Suzuki E, Takasaki S, Asakura K, Suzuki Y, Takagi M, Nakayama T, Watanabe H, Miura K, Mori Y; Michinoku Tocilizumab Study Group. Miyata M, et al. Among authors: nakazawa s. Fukushima J Med Sci. 2023 Apr 5;69(1):11-20. doi: 10.5387/fms.2022-06. Epub 2023 Mar 30. Fukushima J Med Sci. 2023. PMID: 36990790 Free PMC article. Retracted.
Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group.
Hirabayashi Y, Munakata Y, Miyata M, Urata Y, Saito K, Okuno H, Yoshida M, Kodera T, Watanabe R, Miyamoto S, Ishii T, Nakazawa S, Takemori H, Ando T, Kanno T, Komagamine M, Kato I, Takahashi Y, Komatsuda A, Endo K, Murai C, Takakubo Y, Miura T, Sato Y, Ichikawa K, Konta T, Chiba N, Muryoi T, Kobayashi H, Fujii H, Sekiguchi Y, Hatakeyama A, Ogura K, Sakuraba H, Asano T, Kanazawa H, Suzuki E, Takasaki S, Asakura K, Sugisaki K, Suzuki Y, Takagi M, Nakayama T, Watanabe H, Miura K, Mori Y; Michinoku Tocilizumab Study Group. Hirabayashi Y, et al. Among authors: nakazawa s. Mod Rheumatol. 2016 Nov;26(6):828-835. doi: 10.3109/14397595.2016.1160991. Epub 2016 Apr 21. Mod Rheumatol. 2016. PMID: 26934116
Artificial intelligence for volumetric measurement of cerebral white matter hyperintensities on thick-slice fluid-attenuated inversion recovery (FLAIR) magnetic resonance images from multiple centers.
Kuwabara M, Ikawa F, Nakazawa S, Koshino S, Ishii D, Kondo H, Hara T, Maeda Y, Sato R, Kaneko T, Maeyama S, Shimahara Y, Horie N. Kuwabara M, et al. Among authors: nakazawa s. Sci Rep. 2024 May 2;14(1):10104. doi: 10.1038/s41598-024-60789-x. Sci Rep. 2024. PMID: 38698152 Free PMC article.
Fatal tumoral hemorrhage from brain metastases of renal cell carcinoma after stereotactic radiotherapy and immune checkpoint inhibitor and vascular endothelial growth factor-targeted therapy combinations.
Iwasa K, Nakazawa S, Kato T, Hatano K, Kawashima A, Fukuhara S, Nonomura N. Iwasa K, et al. Among authors: nakazawa s. IJU Case Rep. 2024 Mar 4;7(3):225-229. doi: 10.1002/iju5.12708. eCollection 2024 May. IJU Case Rep. 2024. PMID: 38686061 Free PMC article.
Nonmagnetic framboid and associated iron nanoparticles with a space-weathered feature from asteroid Ryugu.
Kimura Y, Kato T, Anada S, Yoshida R, Yamamoto K, Tanigaki T, Akashi T, Kasai H, Kurosawa K, Nakamura T, Noguchi T, Sato M, Matsumoto T, Morita T, Kikuiri M, Amano K, Kagawa E, Yada T, Nishimura M, Nakato A, Miyazaki A, Yogata K, Abe M, Okada T, Usui T, Yoshikawa M, Saiki T, Tanaka S, Terui F, Nakazawa S, Yurimoto H, Okazaki R, Yabuta H, Naraoka H, Sakamoto K, Watanabe SI, Tsuda Y, Tachibana S. Kimura Y, et al. Among authors: nakazawa s. Nat Commun. 2024 Apr 29;15(1):3493. doi: 10.1038/s41467-024-47798-0. Nat Commun. 2024. PMID: 38684653 Free PMC article.
Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.
Pecci F, Nakazawa S, Ricciuti B, Harada G, Lee JK, Alessi JV, Barrichello A, Vaz VR, Lamberti G, Di Federico A, Gandhi MM, Gazgalis D, Feng WW, Jiang J, Baldacci S, Locquet MA, Gottlieb FH, Chen MF, Lee E, Haradon D, Smokovich A, Voligny E, Nguyen T, Goel VK, Zimmerman Z, Atwal S, Wang X, Bahcall M, Heist RS, Iqbal S, Gandhi N, Elliott A, Vanderwalde AM, Ma PC, Halmos B, Liu SV, Che J, Schrock AB, Drilon A, Janne PA, Awad MM. Pecci F, et al. Among authors: nakazawa s. Cancer Discov. 2024 Apr 3. doi: 10.1158/2159-8290.CD-23-1217. Online ahead of print. Cancer Discov. 2024. PMID: 38564707
Pro-Hemorrhagic Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Associated with NOTCH3 p.R75P Mutation with Low Vascular NOTCH3 Aggregation Property.
Ishiyama H, Kim H, Saito S, Takeda S, Takegami M, Yamamoto Y, Abe S, Nakazawa S, Tanaka T, Washida K, Morita Y, Oh ST, Jung HJ, Choi JC, Nakaoku Y, Nakahara J, Koga M, Toyoda K, Amemiya K, Ikeda Y, Hatakeyama K, Mizuta I, Mizuno T, Kim KK, Ihara M. Ishiyama H, et al. Among authors: nakazawa s. Ann Neurol. 2024 Mar 23. doi: 10.1002/ana.26916. Online ahead of print. Ann Neurol. 2024. PMID: 38520151
1,258 results